Lincluden Management Ltd. raised its stake in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 50.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 93,839 shares of the medical equipment provider’s stock after buying an additional 31,530 shares during the period. Zimmer Biomet comprises approximately 0.8% of Lincluden Management Ltd.’s holdings, making the stock its 28th largest position. Lincluden Management Ltd.’s holdings in Zimmer Biomet were worth $11,324,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Longview Partners Guernsey LTD raised its stake in Zimmer Biomet by 6.9% during the 4th quarter. Longview Partners Guernsey LTD now owns 8,027,808 shares of the medical equipment provider’s stock valued at $968,716,000 after buying an additional 521,124 shares during the last quarter. Nordea Investment Management AB increased its stake in shares of Zimmer Biomet by 7.3% in the 3rd quarter. Nordea Investment Management AB now owns 5,277,660 shares of the medical equipment provider’s stock worth $617,961,000 after purchasing an additional 357,302 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Zimmer Biomet by 14.7% in the 4th quarter. American Century Companies Inc. now owns 4,777,397 shares of the medical equipment provider’s stock worth $576,488,000 after purchasing an additional 612,044 shares in the last quarter. Jana Partners LLC increased its stake in shares of Zimmer Biomet by 16.6% in the 3rd quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock worth $545,932,000 after purchasing an additional 662,497 shares in the last quarter. Finally, OppenheimerFunds Inc. increased its stake in shares of Zimmer Biomet by 14.8% in the 4th quarter. OppenheimerFunds Inc. now owns 2,644,596 shares of the medical equipment provider’s stock worth $319,124,000 after purchasing an additional 340,845 shares in the last quarter. Institutional investors and hedge funds own 86.49% of the company’s stock.
Shares of Zimmer Biomet Holdings Inc (NYSE ZBH) opened at $114.75 on Tuesday. The company has a current ratio of 1.50, a quick ratio of 0.81 and a debt-to-equity ratio of 0.76. The stock has a market cap of $23,733.65, a PE ratio of 12.74, a PEG ratio of 2.03 and a beta of 1.13. Zimmer Biomet Holdings Inc has a 1 year low of $108.03 and a 1 year high of $133.49.
Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.10. The firm had revenue of $2.07 billion for the quarter, compared to analysts’ expectations of $2.03 billion. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. The business’s revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the company earned $2.14 EPS. sell-side analysts anticipate that Zimmer Biomet Holdings Inc will post 7.8 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.84%. The ex-dividend date of this dividend is Wednesday, March 28th. Zimmer Biomet’s dividend payout ratio is 10.65%.
In other news, insider Bryan C. Hanson acquired 25,077 shares of Zimmer Biomet stock in a transaction that occurred on Tuesday, February 20th. The shares were bought at an average cost of $119.68 per share, with a total value of $3,001,215.36. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Chad F. Phipps sold 20,826 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $115.95, for a total transaction of $2,414,774.70. The disclosure for this sale can be found here. 1.07% of the stock is currently owned by corporate insiders.
Several research firms have recently commented on ZBH. Cantor Fitzgerald restated a “buy” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research note on Tuesday, January 30th. BMO Capital Markets reaffirmed a “buy” rating and issued a $144.00 target price on shares of Zimmer Biomet in a report on Tuesday, January 30th. SunTrust Banks upped their target price on shares of Zimmer Biomet to $142.00 and gave the stock a “buy” rating in a report on Monday, January 29th. Morgan Stanley upped their target price on shares of Zimmer Biomet from $140.00 to $150.00 in a report on Monday, January 29th. Finally, Needham & Company LLC upped their target price on shares of Zimmer Biomet from $144.00 to $155.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 30th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $140.63.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.